NEW YORK, Oct. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0650496/The-Global-Competitive-Landscape-of-Antibody-Drug-Development-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the antibody drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of antibody drugs in cancer is split between the 34% which have unique drug target strategies and the other part (66%) which have head-to-head target competing antibody drugs in 76 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the antibody drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, ERBB2 and EGFR.

* Eight out of ten drug target strategies in Phase II development are new to antibody drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (30%) and Phase II development (21%).

* The highest number of described target strategies among antibody drugs are found in Colorectal Cancer, Ovarian Cancer and Prostate Cancer. Antibody drugs are experiencing targeting competition in five out of every nine cancer indications described, and more so in Breast Cancer, Colorectal Cancer and non-Hodgkin's Lymphoma. Here, Ewing's Sarcoma makes out its own class by having five drugs but only towards one target strategy.

* The highest number of described drug target strategies of antibody drugs belongs to Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Immunomedics. However, when looking at the total number of drugs the order of the companies shifts into Hoffmann-La Roche, Immunomedics, Bristol-Myers Squibb, AstraZeneca and Eli Lilly.

* From an indication perspective it is Hoffmann-La Roche, Eli Lilly, Amgen, Pfizer and Bristol-Myers Squibb which take the lead in the widest coverage of cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any antibody drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1469

Table 255: InNexus Biotechnology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1474

Table 256: Intracel's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1485

Table 257: ISA Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1489

Table 258: ISU ABXIS's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1493

Table 259: Johnson & Johnson's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1498

Table 260: Kaketsuken's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1505

Table 261: KaloBios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1508

Table 262: Kirin Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1511

Table 263: Kissei's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1516

Table 264: Kyowa Hakko Kirin's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1521

Table 265: Kyto Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1525

Table 266: LFB Biotechnologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1528

Table 267: LG Life Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1536

Table 268: MacroGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1541

Table 269: MAT Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1547

Table 270: Medarex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1552

Table 271: MediGene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1557

Table 272: MedImmune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1561

Table 273: Menarini's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1565

Table 274: Merck & Co's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1569

Table 275: Merck KGaA's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1574

Table 276: Merrimack's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1583

Table 277: Micromet's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1587

Table 278: Mitsubishi Tanabe Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1601

Table 279: Mycenax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1604

Table 280: Neovacs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1607

Table 281: Neuren's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1611

Table 282: NIH's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1614

Table 283: NKT Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1618

Table 284: Non-industrial Sources' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1621

Table 285: Northwest Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1627

Table 286: Novartis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1630

Table 287: OncoMed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1638

Table 288: Oncothyreon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1642

Table 289: Onyvax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1646

Table 290: Oxford BioMedica's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1649

Table 291: Paladin Labs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1652

Table 292: Panacea's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1658

Table 293: PanGenetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1663

Table 294: Patrys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1667

Table 295: Pepscan Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1672

Table 296: Peregrine Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1676

Table 297: Perseus Proteomics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1681

Table 298: Pfizer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1684

Table 299: Philogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1699

Table 300: Pierre Fabre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1703

Table 301: Prima Biomed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1711

Table 302: ProCell Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1714

Table 303: Prochon Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1717

Table 304: Progenics Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1721

Table 305: Ramot's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1724

Table 306: Recepta biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1727

Table 307: Receptor BioLogix's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1730

Table 308: Regeneron's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1734

Table 309: Sanofi-Aventis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1741

Table 310: SBI Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1747

Table 311: Scancell's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1750

Table 312: Seattle Genetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1753

Table 313: Shenogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1760

Table 314: Stainwei Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1763

Table 315: Sunol Molecular's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1766

Table 316: SuppreMol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1769

Table 317: Switch Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1772

Table 318: Symphogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1775

Table 319: Synageva BioPharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1780

Table 320: SynerGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1788

Table 321: Takeda's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1791

Table 322: Targa Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1794

Table 323: TeGenero's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1800

Table 324: Teva's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1803

Table 325: Therapure Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1808

Table 326: ThromboGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1811

Table 327: Titan Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1816

Table 328: Tolerx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1821

Table 329: Tracon Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1825

Table 330: Transgene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1828

Table 331: Trillium Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1831

Table 332: Trion Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1834

Table 333: UCB's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1841

Table 334: United Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1846

Table 335: Vaccinex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1849

Table 336: VasGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1857

Table 337: Viragen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1860

Table 338: Viventia Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1864

Table 339: Wakunaga's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1867

Table 340: Wilex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1871

Table 341: XBiotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1874

Table 342: Xencor's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1878

Table 343: Xerion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1893

Table 344: Xoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1898

Table 345: Y's Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1902

Table 346: YM BioSciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1906

Table 347: Zenotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1911Pharmaceuticals 1816

9.179 Tolerx 1821

9.180 Tracon Pharmaceuticals 1825

9.181 Transgene 1828

9.182 Trillium Therapeutics 1831

9.183 Trion Pharma 1834

9.184 UCB 1841

9.185 United Therapeutics 1846

9.186 Vaccinex 1849

9.187 VasGene Therapeutics 1857

9.188 Viragen 1860

9.189 Viventia Biotech 1864

9.190 Wakunaga 1867

9.191 Wilex 1871

9.192 XBiotech 1874

9.193 Xencor 1878

9.194 Xerion 1893

9.195 Xoma 1898

9.196 Y's Therapeutics 1902

9.197 YM BioSciences 1906

9.198 Zenotech 1911

10 Disclaimer 1917

11 Drug Index 1918

12 Company Index 1934

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Oncology 383

Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Oncology - Large Clusters 385

Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Oncology - Smaller Clusters 386

Figure 4: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Larger Clusters 387

Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Smaller Clusters 388

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35

Table 3: Head to Head Target Competition among Antibody Drugs in Oncology 35

Table 4: Overview of Drug Target Strategy Themes 40

Table 5: Terminally Ceased Targets of Antibody Drugs in Oncology 41

Table 6: Official Gene Name to Target Profle 42

Table 7: Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 370

Table 8: Identity of Drug Targets with Available Biological Structures 376

Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Oncology 381

Table 10: Available Protein Expression Profiles of Antibody Drug Targets in Oncology 389

Table 11: Pathway Summary 394

Table 12: Drug Targets without any Identified Assigned Pathways 394

Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 397

Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 411

Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 427

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 431

Table 17: Top Competitive Target Strategies of Antibody Drugs in Oncology 432

Table 18: New and Unique Target Strategies of Pre-registration and Marketed Antibody Drugs in Oncology 435

Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Oncology being Marketed or in Pre-registration 436

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Oncology 437

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology 438

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Oncology 439

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology 442

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Oncology 444

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology 448

Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Oncology 449

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology 454

Table 28: Target Strategies of Suspended and Terminated Antibody Drugs in Oncology 458

Table 29: Connecting Target Strategy with Its Profile Identification Number 463

Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Oncology 761

Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 770

Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 772

Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 773

Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 774

Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 775

Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 776

Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 777

Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 778

Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 779

Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 779

Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 780

Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 781

Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 782

Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 783

Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 784

Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 785

Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 786

Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 788

Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 790

Table 50: Target Strategy Development Profiles of Antibody Compounds for Cancer Diagnosis 791

Table 51: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Compounds 792

Table 52: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer Fatigue 793

Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid 794

Table 54: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 795

Table 55: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 795

Table 56: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 796

Table 57: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 797

Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 799

Table 59: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 799

Table 60: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 800

Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 801

Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 802

Table 63: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 804

Table 64: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 806

Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma 807

Table 66: The Competition through Close Mechanistic Approximation between Ewing's Sarcoma Drugs 807

Table 67: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 808

Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 809

Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 809

Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 810

Table 71: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 811

Table 72: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 812

Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 813

Table 74: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 813

Table 75: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 814

Table 76: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 814

Table 77: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 815

Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 816

Table 79: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 817

Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma 818

Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 819

Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 820

Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 821

Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 822

Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 823

Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 824

Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 825

Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 826

Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 827

Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant Ascites 828

Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 829

Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 830

Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 831

Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 832

Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 833

Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 833

Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 834

Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 836

Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 837

Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 838

Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 839

Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 840

Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma 841

Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 843

Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 845

Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 847

Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 848

Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 849

Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 850

Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 851

Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 851

Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 852

Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 854

Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 855

Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 857

Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 858

Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 859

Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 860

Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 861

Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 863

Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Anemia 864

Table 122: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 865

Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Mucositis 866

Table 124: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Thrombocytopenia 867

Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 868

Table 126: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 869

Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 870

Table 128: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 870

Table 129: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 871

Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 872

Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 873

Table 132: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 874

Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 875

Table 134: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 876

Table 135: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 878

Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 879

Table 137: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 879

Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 880

Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 881

Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 882

Table 141: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 883

Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 884

Table 143: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 884

Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication 885

Table 145: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 889

Table 146: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 892

Table 147: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom`s hypergammaglobulinemia 893

Table 148: The Competition through Close Mechanistic Approximation between Waldenstrom`s hypergammaglobulinemia Drugs 893

Table 149: Competitive Summary by Investigator of Antibody Drug Development 894

Table 150: Summary Table of Corporate Changes in the Competitive Landscape of Antibody Drug Development in Oncology 898

Table 151: Example of a Competitive Fall-Out Table (Targeting ERBB2/Modified) 900

Table 152: A&G Pharmaceutical's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 902

Table 153: Abbott's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 905

Table 154: Abiogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 912

Table 155: Ablynx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 919

Table 156: AC Immune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 923

Table 157: Acceleron Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 926

Table 158: Access'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 929

Table 159: Actinium Pharmaceuticals'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 934

Table 160: Active Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 938

Table 161: Adherex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 942

Table 162: Affibody's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 945

Table 163: Affimed Therapeutics'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 950

Table 164: Affitech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 958

Table 165: AGY Therapeutics'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 964

Table 166: Aida Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 967

Table 167: Alder Biopharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 971

Table 168: Alethia Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 976

Table 169: Alexion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 979

Table 170: Alfacell's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 983

Table 171: Algeta's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 986

Table 172: ALSP's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 991

Table 173: Altor BioScience's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 996

Table 174: Amgen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 999

Table 175: Amorfix Life Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1012

Table 176: Antisoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1016

Table 177: Aphios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1022

Table 178: Apricus Biosciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1026

Table 179: Arana Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1032

Table 180: Arca biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1035

Table 181: arGEN-X's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1039

Table 182: Astellas' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1043

Table 183: AstraZeneca's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1047

Table 184: Avaxia's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1062

Table 185: AVEO's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1066

Table 186: Bayer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1074

Table 187: Berkeley Lab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1078

Table 188: Biocon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1081

Table 189: Biogen Idec's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1084

Table 190: BioInvent's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1097

Table 191: Biolex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1101

Table 192: BioLineRx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1105

Table 193: Biosceptre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1108

Table 194: Biotecnol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1111

Table 195: Biotest's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1117

Table 196: Boehringer Ingelheim's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1120

Table 197: Bristol-Myers Squibb's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1123

Table 198: BTG's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1141

Table 199: Cancer Innovations' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1145

Table 200: Cancer Research Technology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1148

Table 201: Celldex Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1162

Table 202: Celltrion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1169

Table 203: Celtic Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1176

Table 204: Center of Molecular Immunology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1180

Table 205: CG Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1186

Table 206: Circadian Technologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1189

Table 207: CSL's Included Antibo

To order this report:

Pathology Industry: The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker